LIPANTHYL®



Composition per capsule :

Fenofibrate (INN) 300 mg. Excipient qs 342 mg.

Indications:

For adults only. Patients with hypercholesterolemia (type IIa) or with pure (type IV) or combined (types IIb and III) endogenous hypertrigliceridemia. - when appropriate caloric restriction alone has been unsuccessful in achieving desired lipid reduction.

- more particularly when cholesterol levels are still high following dietary treatment and/or with existing associated risk factors .

Dietary control should be continued as an adjunct to drug treatment.

No long-term controlled trials are available to establish whether or not fenofibrate has a beneficial effect in the primary or secondary prevention of atherosclerosis related complications.

Contra-indications:

- Severe renal or hepatic dysfunction, - Children.

Precautions

- Concurrent use of other drugs (anticoagulants) - Pregnancy - Lactation. Should be notified to the physician before starting treatment.

EFFECTS ON ACTIVITIES REQUIRING ALERTNESS SUCH AS DRIVING A MOTOR VEHICLE OR OPERATING HEAVY MACHINERY OR APPLIANCES.

No case of drowsiness has been reported.

Adverse reactions :

Seldom seen and mild: - Digestive symptoms (gastric or intestinal upset) - Skin allergic reactions - Transient elevation of transaminases.

Dosage and administration :

As physician directs.

One 300 mg capsule daily with one of the principal meals as an adjunct to dietary measures.

Storage :

Store below 30°c, in dry place

Availability:

Capsules in blister pack cartons of 30.

MINAPHARM

Under Licence of FOURNIER - FRANCE





